When Frederick Banting, Charles Best, and James Collip filed for a U.S. patent on insulin in 1923 and sold it to the University of Toronto for $1 each, they did it because, as Best once said, “insulin belongs to the world.” They also believed that securing the patent was a form of publication, and wrote to the university president, “When the details of the method of preparation are published anyone would be free to prepare the extract, but no one could secure a profitable monop...
READ MORE
|
The National Institute of Health and Care Excellence (NICE) has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight blood cancer. The treatment will now be available on the NHS for patients with a form of blood cancer as a first- and second-line drug, after a new guideline recommended it in combination with dexamethasone as an option for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant and cannot take thalido...
READ MORE
|
A groundbreaking drug, rifampin, could help to end the global tuberculosis epidemic, according to researchers. Clinical trials carried out at the McGill University Health Centre showed that rifampin is less toxic and is more effective than the standard of care treatment, isoniazid. The results of two trials, conducted across a number of countries, were promising and showed that four months treatment with rifampin was non-inferior to a nine-month regime of isoniazid. Although the World Health Org...
READ MORE
|
Merck, a leading science and technology company, today announced that the CEO of its life science business, Udit Batra, was named “CEO of the Year” for 2016 by CPhI Pharma for his commitment to furthering life science innovation globally....
READ MORE
|
When health care providers order a test or prescribe medicine, they want to be 100 percent confident in their decision. That means being able to explain their decision and study it over, depending upon how a patient responds. As artificial intelligence’s footprint increases in medicine, that ability to check work and follow the path of a decision can become a bit muddied. That’s why the discovery of a once-hidden through-line between two popular predictive models used in artificial i...
READ MORE
|
US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....
PHARMACEUTICAL-TECHNOLOGY.COM
READ MORE
|